| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/09/2006 | WO2006026356A2 S-TRIAZOLYL α-MERCAPTOACETANILDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE |
| 03/09/2006 | WO2006026348A1 Use of the combination comprising temozolomide and tnf-alpha for treating glioblastoma |
| 03/09/2006 | WO2006026316A2 Prodrug substituted benzoxazoles as estrogenic agents |
| 03/09/2006 | WO2006026313A2 Cancer treatment method |
| 03/09/2006 | WO2006026275A2 Methods for inducing uterine contraction and compositions useful therefor |
| 03/09/2006 | WO2006026273A2 Method of treating atherosclerosis, dyslipidemias and related conditions |
| 03/09/2006 | WO2006026260A1 Histone deacetylase inhibitors |
| 03/09/2006 | WO2006026251A1 Materials and methods for the treatment of depression |
| 03/09/2006 | WO2006026215A1 Compositions containing alpha-2-adrenergic agonist components |
| 03/09/2006 | WO2006026204A2 Novel gamma-lactams as beta-secretase inhibitors |
| 03/09/2006 | WO2006026196A2 Androgen receptor modulators |
| 03/09/2006 | WO2006026115A2 Boot disk management utility |
| 03/09/2006 | WO2006026095A2 Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid |
| 03/09/2006 | WO2006026083A2 Nasal delivery of cyclodextrin complexes of anti-inflammatory steroids |
| 03/09/2006 | WO2006026034A2 Processes for the preparation of isothiazole derivatives |
| 03/09/2006 | WO2006026033A2 Novel chalcogenoxanthylium dyes for purging blood pathogens and for photodynamic therapy |
| 03/09/2006 | WO2006025988A1 Use of alk 5 inhibitors to modulate or inhibit myostatin activity leading to increased lean tissue accretion in animals |
| 03/09/2006 | WO2006025979A2 Modulators of nuclear receptors |
| 03/09/2006 | WO2006025939A1 Crystalline forms of 1,24(s)-dihydroxy vitamin d2 |
| 03/09/2006 | WO2006025924A2 Alpha, beta-unsaturated sulfones, sulfoxides, sulfonimides, sulfinimides, acylsulfonamides and acylsulfinamides and therapeutic uses thereof |
| 03/09/2006 | WO2006025920A2 Modulators of central nervous system neurotransmitters |
| 03/09/2006 | WO2006025889A2 Inhibition of atherosclerosis by diindolylmethane analogs |
| 03/09/2006 | WO2006025882A2 Absorption enhancers for drug administration |
| 03/09/2006 | WO2006025708A2 Inhibitor for acetylcholinesterase containing gamma-viniferin or visitin a |
| 03/09/2006 | WO2006025598A1 Suppressant for cerebral infarction attributed to long-time ischemia |
| 03/09/2006 | WO2006025583A1 External preparation of s/o type |
| 03/09/2006 | WO2006025567A1 Novel substituted imidazole derivatives |
| 03/09/2006 | WO2006025517A1 Sodium channel inhibitor |
| 03/09/2006 | WO2006025490A1 Molecular chaperone function regulator |
| 03/09/2006 | WO2006025475A1 Novel carbapenem compound |
| 03/09/2006 | WO2006025471A1 Piperidine derivative or pharmaceutically acceptable salt thereof |
| 03/09/2006 | WO2006025431A1 Antagonist against tolerance to anticancer drugs |
| 03/09/2006 | WO2006025395A1 Drug and treating system for chronic obstructive pulmonary disease by using carrier-free cell growth factor |
| 03/09/2006 | WO2006025378A1 Remedy for hyperlipemia |
| 03/09/2006 | WO2006025324A1 Tropan compound |
| 03/09/2006 | WO2006025307A1 Wrinkle reduction agent, lipolysis accelerator, composition for external use on skin, and food or beverage composition |
| 03/09/2006 | WO2006025286A1 Constitutional function-improving agents |
| 03/09/2006 | WO2006025267A1 Remedy for sleep disorders using lowering in per2 protein level as the action mechanism |
| 03/09/2006 | WO2006025251A1 Physiologically active substances biselide a, biselide b, and biselide c, processes for producing these, and uses of these |
| 03/09/2006 | WO2006025247A1 Mitochondria activators |
| 03/09/2006 | WO2006025070A2 Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol |
| 03/09/2006 | WO2006025069A2 Tricyclic pyrazole derivatives as cannabinoid receptor modulators |
| 03/09/2006 | WO2006025051A2 Process of preparing a crystalline azithromycin monohydrate |
| 03/09/2006 | WO2006024958A2 Cannabinoid compositions and methods of use thereof |
| 03/09/2006 | WO2006024955A1 Azabicyclic amine histamine-3 receptor antagonists |
| 03/09/2006 | WO2006024947A2 Methods and materials relating to enhanced production of dopamine neurons |
| 03/09/2006 | WO2006024942A1 Androgen modulators |
| 03/09/2006 | WO2006024932A1 2-amino-quinazoline derivatives useful as inhibitors of b-secretase (bace) |
| 03/09/2006 | WO2006024931A2 Therapeutic combinations comprising a selective estrogen receptor modulator and a selective androgen receptor modulator |
| 03/09/2006 | WO2006024930A1 Novel co-crystals between polyethylene glycols and 5-phenylpyrazolyl-1-benzenesulfonamides |
| 03/09/2006 | WO2006024881A2 Multiparticulates of preferably an opioid, and method of manufacturing using extrusion |
| 03/09/2006 | WO2006024863A1 Stable crystal form of imatinib mesylate and process for the preparation thereof |
| 03/09/2006 | WO2006024823A1 Pyrimidine sulphonamide derivatives as chemokine receptor modulators |
| 03/09/2006 | WO2006024784A2 Aminoglycoside analogues, uses thereof for treating microbial diseases and synthesis thereof |
| 03/09/2006 | WO2006024777A1 Pyrrole derivatives, their preparation and their therapeutic use |
| 03/09/2006 | WO2006024776A1 N(1 h-indolyl)-1 h-indole-2-carb0xamide derivatives, their preparation and their therapeutic use |
| 03/09/2006 | WO2006024770A2 Phosphole derivatives complexed with metals, and pharmaceutical uses thereof |
| 03/09/2006 | WO2006024769A1 Use of dendrimers to stimulate cell growth |
| 03/09/2006 | WO2006024742A1 Food supplement for livestock and implementing method thereof |
| 03/09/2006 | WO2006024741A2 Hybrid qa molecules wherein q is an aminoquinoline and a is an antibiotic residue, their synthesis and their uses as antibacterial agent |
| 03/09/2006 | WO2006024699A1 Thioxothiazolidinone compounds for use as pharmaceuticals |
| 03/09/2006 | WO2006024689A1 Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency |
| 03/09/2006 | WO2006024685A1 Combined use of pterostilbene and quercetin for the production of cancer treatment medicaments |
| 03/09/2006 | WO2006024675A1 Use of alkylphospholipids for the treatment of solid tumours |
| 03/09/2006 | WO2006024668A1 Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile |
| 03/09/2006 | WO2006024667A1 Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile |
| 03/09/2006 | WO2006024666A1 Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors |
| 03/09/2006 | WO2006024628A1 Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
| 03/09/2006 | WO2006024627A2 N-2 adamantanyl-2-phenoxy-acetamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
| 03/09/2006 | WO2006024545A1 Fused bicyclic natural compounds and their use as inhibitors of parp and parp-mediated inflammatory processes |
| 03/09/2006 | WO2006024535A1 Substituted indole compounds and their use as 5-ht6 receptor modulators |
| 03/09/2006 | WO2006024492A2 Medical implant provided with inhibitors of atp synthesis |
| 03/09/2006 | WO2006024491A1 Methods and compositions for the treatment of cell proliferation |
| 03/09/2006 | WO2006024490A2 Methods and compositions for the treatment of cell proliferation |
| 03/09/2006 | WO2006024489A2 Methods and compositions for the treatment of cell proliferation |
| 03/09/2006 | WO2006024488A2 Medical stent provided with inhibitors of atp synthesis |
| 03/09/2006 | WO2006024479A2 Pharmaceutical multiparticulate compositions comprising mycophenolic acid or mycophenolate sodium and combination compositions with rapamycin |
| 03/09/2006 | WO2006024390A1 Hexahydro-pyrazino[1,2-a]pyrimidine-4, 7-dione derivatives substituted with amino acids |
| 03/09/2006 | WO2006024236A1 Medicine having analgesic effects |
| 03/09/2006 | WO2006024121A1 Use of n-phenylpiperazine derivatives and pharmaceutical compositions containing them |
| 03/09/2006 | WO2006015035A8 Useful compounds for hpv infection |
| 03/09/2006 | WO2006008470A3 Treatment of tumours |
| 03/09/2006 | WO2006004924A3 Imidazolo-related compounds, compositions and methods for their use |
| 03/09/2006 | WO2006004757A3 Topical formulations for treating allergic diseases |
| 03/09/2006 | WO2006004703A3 PYRROLO[2,3-d]PYRIMIDINES THAT MODULATE ACK1 AND LCK ACTIVITY |
| 03/09/2006 | WO2005121109A3 Novel antiviral macrocycle derivatives and metal complexes, incorporating bridged macrocycles |
| 03/09/2006 | WO2005116640A3 Identification of anti-prion drugs by high-throughput screening based on sift |
| 03/09/2006 | WO2005115428A3 Supplement containing carotenoid, nicotinamide, zinc, water soluble extract of uncaria species and method using the same |
| 03/09/2006 | WO2005115379A3 Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux |
| 03/09/2006 | WO2005115358A3 Intranasal delivery of nucleic acid molecules |
| 03/09/2006 | WO2005112963A3 Phytomedicinal compositions for the control of lipid accumulation and metabolism in mammals |
| 03/09/2006 | WO2005112922A9 Benzamide compounds |
| 03/09/2006 | WO2005110477A3 Combination therapies for cancer and proliferative angiopathies |
| 03/09/2006 | WO2005110387A8 Systems and methods for administering a medical regimen |
| 03/09/2006 | WO2005110384A3 Apiary veterinary composition |
| 03/09/2006 | WO2005099754A3 Maytansinoid analogs as antitumor agents |
| 03/09/2006 | WO2005098444A3 Monocarboxylate transporters expressed in cancer cells |
| 03/09/2006 | WO2005097792A8 Device and method for pneumatic valve control |
| 03/09/2006 | WO2005097751A3 Non-imidazole heterocyclic compounds as histamine h3-receptor ligands |
| 03/09/2006 | WO2005092442A3 Method and compositions for treatment of chronic neuropathic pain |